Recombinant interferon α2a synergistically enhances gancielovir-mediated tumor cell killing in the herpes simplex virus thymidine kinase system

Cancer Gene Therapy

Volumn 6, Issue 5, 1999, Pages 402-408

  Whartenby, Katharine A ^a   Darnowski, James W ^a   Freeman, Scott M ^b,c   Yurasha, Kimberly ^a   Calabresi, Paul ^a  

^a RHODE ISLAND HOSPITAL   (United States)

^b TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Bystander effect; Cancer; Ganciclovir; Gene therapy; Herpes simplex virus thymidine kinase; Interferon

Indexed keywords

ALPHA2A INTERFERON; GANCICLOVIR; THYMIDINE KINASE;

ANIMAL; APOPTOSIS; ARTICLE; BAGG ALBINO MOUSE; CELL CULTURE; DNA REPLICATION; DRUG EFFECT; DRUG POTENTIATION; ENZYMOLOGY; FEMALE; FIBROSARCOMA; GENETICS; HERPES SIMPLEX VIRUS; HUMAN; MOUSE; OVARY TUMOR; PATHOLOGY;

ANIMALS; APOPTOSIS; DNA REPLICATION; DRUG SYNERGISM; FEMALE; FIBROSARCOMA; GANCICLOVIR; HUMANS; INTERFERON ALFA-2A; MICE; MICE, INBRED BALB C; OVARIAN NEOPLASMS; SIMPLEXVIRUS; THYMIDINE KINASE; TUMOR CELLS, CULTURED;

EID: 0033191074     PISSN: 09291903     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.cgt.7700063     Document Type: Article

References (20)

1. Elion GB. The chemotherapeutic exploitation of virus-specific enzymes. Adv Enzyme Regul. 1980;18:53-66.
2. St. Clair MH, Lambe CU, Furman PA. Inhibition by ganciclovir of cell growth and DNA synthesis of cells biochemically transformed with herpesvirus genetic information. Antimicrob Agents Chemother. 1987;31:844-847.
3. Oliver S, Bubley G, Crumpacker C. Inhibition of HSV-transformed murine cells by nucleoside analogs 2′-NDG and 2′-nor-GMP. Virology. 1985;145:84-93.
4. Freeman SM, McCune CS, Abboud CN, Abraham GN. Treatment of ovarian cancer using HSV-TK gene-modified cells. Hum Gene Ther. 1992;3:342.
5. Freeman SM, Whartenby KA, Koeplin DS, Moolten FL, Abboud CN, Abraham GN. Tumor regression when a fraction of the mass contains the HSV-TK gene. J Cell Biochem. 1992;16F:47.
6. Freeman SM, Abboud CN, Whartenby KA, Abraham GN. The bystander effect: tumor regression when a fraction of the mass is genetically modified. Cancer Res. 1993;53: 5274-5283.
7. Culver KW, Ram Z, Wallbridge S, Ishii H, Oldfield EH, Blaese RM. In vivo gene transfer with retroviral vector producer cells for treatment of experimental brain tumors. Science. 1992;256:1550-1552.
8. Benedetti S, Dimeco F, Pollo B, et al. Limited efficacy of the HSV-TK/GCV system for gene therapy of malignant gliomas and perspectives for the combined transduction of the interleukin 4 gene. Hum Gene Ther. 1997;8:1345-1353.
9. Ramesh R, Munshi A, Munshi A, Abboud CN, Freeman SM. In vivo analysis of the bystander effect: a cytokine cascade. Exp Hematol. 1996;24:829-838.
10. Taylor JL, Punda-Polic V, O'Brien WJ. Combined antiherpes virus activity of nucleoside analogs and interferon. Curr Eye Res. 1991;10 Suppl:205-211.
11. Taylor JL, Tom P, Guy J, Selvarajan RM, O'Brien WJ. Regulation of herpes simplex virus thymidine kinase in cells treated with a synergistic antiviral combination of α interferon and acyclovir. Antimicrob Agents Chemother. 1994;38:853-856.
12. Darnowski JW, Davol P, Goulette FA. Human recombinant interferon α2a plus 3′-azido-3′-deoxythymidine: synergistic growth inhibition with evidence of impaired DNA repair in human colon adenocarcinoma cells. Biochem Phannacol. 1997;53:571-580.
13. Lowik CWGM, Alblas M, van de Ruit M, Papapoulos SE, van der Pluijin G. Quantification of adherent and nonadherent cells cultured in 96-well plates using the supravital stain neutral red. Anal Biochem. 1993;213:426-433.
14. Ramesh R, Munshi A, Marrogi AJ, Freeman SM. Enhancement of tumor killing using a combination of tumor immunization and HSV-tk suicide gene therapy. Int J Cancer. 1998;29:380-386.
15. Santodonato L, Ferrantini M, Gabriele L, et al. Cure of mice with established metastatic friend leukemia cell tumors by a combined therapy with tumor cells expressing both interferon α1 and herpes simplex thymidine kinase followed by ganciclovir. Hum Gene Ther. 1996;7:1-10.
16. Santodonato L, D'Agostino G, Santini SM, et al. Local and systemic antitumor response after combined therapy of mouse metastatic tumors with tumor cells expressing IFN α and HSVtk: perspectives for the generation of cancer vaccines. Gene Ther. 1997;4:1246-1255.
17. Bi WL, Parysek L, Warnick R, Sambrook PJ. In vitro evidence that metabolic cooperation is responsible for the bystander effect observed with HSV-TK retroviral gene therapy. Hum Gene Ther. 1993;4:725-730.
18. Fick J, Barker FG, Dazin P, Westphale EM, Beyer EC, Israel MA. The extent of heterocellular communication mediated by gap junctions is predictive of bystander tumor cytotoxicity in vitro. Proc Natl Acad Sci USA. 1995;92: 11071-11075.
19. Mesnil M, Piccoli C, Tiraby G, Willecke K, Yamasaki H. Bystander killing of cancer cells by herpes simplex virus thymidine kinase gene is mediated by connexins. Proc Natl Acad Sci USA. 1996;93:1831-1835.
20. Haberkorn U, Altmann A, Morr I, et al. Monitoring gene therapy with herpes simplex virus thymidine kinase in hepatoma cells: uptake of specific substrates. J Nucl Med. 1997;38:287-294. Author query A: Please provide zip code for Tulane University Medical Center.